MoonLake Immunotherapeutics (MLTX) 2025 Capital Markets Day April 29, 2025 02:15 PM ET Speaker0 Good morning. Good afternoon. Welcome to the capital markets update of Moon Lake Immunotherapeutics. My name is Matthias Bodenstadt. I'm the chief financial officer of the company. With me here today are CEO and co founder, Georges Santos Dasilva and our CSO and co founder, Professor Christian Reich. It's a pleasure to have you here today for the capital markets update. We have a very exciting agenda. We will pro ...

Core Insights - Scinai Bioservices, a CDMO unit launched by Scinai in 2024, operates from a facility in Jerusalem, Israel, featuring 1,850 square meters of clean rooms and laboratories compliant with cGMP standards [2][3] - The CDMO unit has engaged in drug development projects for various biotech companies, including upstream and downstream process development, scale-up, and drug manufacturing for clinical trials [3] - Scinai's U.S. subsidiary, Scinai Bioservices Inc., aims to support early-stage biotech companies in the U.S. by providing essential CDMO services that are currently in short supply [4] Company Overview - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) operates two business units: one focused on developing biological therapeutic products for inflammation and immunology, and the other providing CDMO services to early-stage biotech companies [5] - The company is actively seeking partnerships with potential pharma partners in the fields of inflammation and immunology, as well as institutional and private investors interested in its value proposition [7]